Identification of a surrogate marker for infection in the african green monkey model of inhalation anthrax

Infection and Immunity

Volumn 76, Issue 12, 2008, Pages 5790-5801

  Rossi, Cynthia A ^a   Ulrich, Melanie ^a,c   Norris, Sarah ^a   Reed, Douglas S ^a,d   Pitt, Louise M ^a   Leffel, Elizabeth K ^a,b  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c Hagerstown Community College   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BACTEREMIA; BACTERIAL MEMBRANE; BACTERIAL SPORE; BLOOD CELL COUNT; CERCOPITHECIDAE; CHEMOLUMINESCENCE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; FEVER; HEART RATE; IMMUNOASSAY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SURVIVAL; TELEMETRY;

ANIMALS; ANTHRAX; ANTIGENS, BACTERIAL; BACTERIAL CAPSULES; BIOLOGICAL MARKERS; CERCOPITHECUS AETHIOPS; CHEMILUMINESCENT MEASUREMENTS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOASSAY; INHALATION EXPOSURE; MALE; POLYMERASE CHAIN REACTION;

EID: 57349085019     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00520-08     Document Type: Article

References (55)

1. Albrink, W. S. 1961. Pathogenesis of inhalation anthrax. Bacteriol. Rev. 25:268-273.
2. Aroura, N., and S. H. Leppla. 1993. Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides. J. Biol. Chem. 268:3334-3341.
3. Berdjis, C. C., C. A. Gleiser, H. A. Hartmen, R. W. Kuehne, and W. S. Gochenour. 1962. Pathogenesis of respiratory anthrax in Macaca mulatta. Br. J. Exp. Pathol. 43:515-524.
4. Binhazim, A. A., S. S. Shin, W. L. Chapman, Jr., and J. Olobo. 1993. Comparative susceptibility of African green monkeys (Cercopithecus aethiops) to experimental infection with Leishmania leishmania donovani and Leishmania leishmania infantum. Lab. Anim. Sci. 43:37-47.
5. Brachman, P. S. 1980. Inhalation anthrax. Ann. N. Y. Acad. Sci. 353:83-93.
6. Christensen, D. R., L. J. Hartman, B. M. Loveless, M. S. Frye, M. A. Shipley, D. L. Bridge, M. J. Richards, R. S. Kaplan, J. Garrison, C. D. Baldwin, D. A. Kulesh, and D. A. Norwood. 2006. Detection of biological threat agents by real-time PCR: comparison of assay performance on the R.A.P.I.D., the LightCycler, and the Smart Cycler platforms. Clin. Chem. 52:141-145.
7. Collier, R., and J. Young. 2003. Anthrax toxins. Annu. Rev. Cell Dev. Biol. 19:45-70.
8. Coyne, S. R., P. D. Craw, D. A. Norwood, and M. P. Ulrich. 2004. Comparative analysis of the Schleicher and Schuell IsoCode Stix DNA isolation device and the Qiagen QIAamp DNA mini kit. J. Clin. Microbiol. 42:4859-4862.
9. Duesbery, N. S., C. P. Webb, S. H. Leppla, V. M. Gordon, K. R. Klimpel, T. D. Copeland, et al. 1998. Proteolytic inactivation of MAP kinase-kinase by anthrax lethal factor. Science 280:734-737.
10. Durbin, A. P., C. J. Cho, W. R. Elkins, L. S. Wyatt, B. Moss, and B. R. Murphy. 1999. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies. J. Infect. Dis. 179:1345-1351.
11. Durbin, A. P., W. R. Elkins, and B. R. Murphy. 2000. African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types-1, -2, and -3 infection. Vaccine 18:2462-2469.
12. Ezzell, J. W., T. G. Abshire, and C. Brown. 1999. Analysis of Bacillus anthracis vegetative cell surface antigens and of serum protease cleavage of protective antigen, p. 43-44. In Proceedings of the International Workshop on Anthrax, 1990. Salisbury Printing Co., Wiltshire, United Kingdom.
13. FDA. CFR title 21, food and drugs - part 314. www.accessdata.fda. gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm.
14. Fish, D. C., and R. E. Lincoln. 1968. In vivo-produced anthrax toxin. J. Bacteriol. 95:919-924.
15. Franz, D. R., P. B. Jahrling, A. M. Friedlander, D. J. McClain, D. L. Hoover, W. R. Bryne, J. A. Pavlin, G. W. Christopher, and E. M. Eitzen, Jr. 1997. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 278:399-411.
16. Friedlander, A. M. 2000. Anthrax: clinical features, pathogenesis, and potential biological warfare threat. Curr. Clin. Top. Infect. Dis. 20:335-349.
17. Fritz, D. L., N. K. Jaax, W. B. Lawrence, K. J. Davis, M. L. Pitt, J. W. Ezzell, and A. M. Friedlander. 1995. Pathology of experimental inhalation anthrax in the rhesus monkey. Lab. Investig. 73:691-702.
18. Forino, M., S. Johnson, T. Y. Wong, D. V. Rozanov, A. Y. Savinov, W. L. R. Fattorusso, B. Becattini, A. J. Orry, D. Jung, R. A. Abagyan, J. W. Smith, K. Alibek, R. C. Liddington, A. Y. Stongin, and M. Pellecchia. 2005. Efficient synthetic inhibitors of anthrax lethal factor. Proc. Natl. Acad. Sci. USA 102:9499-9504.
19. Foster, C. D., T. C. Hunter, P. H. Gibbs, and E. K. Leffel. 2008. Comparison of whole-body plethysmography in jacketed and non-jacketed African green monkeys (Chlorocebus aethiops). J. Am. Assoc. Lab. Anim. Sci. 47:52-55.
20. Gamble, C. S., K. O. Jacobsen, E. K. Leffel, and M. L. Pitt. 2007. Use of a low-concentration heparin solution to extend the life of central venous catheters in African green monkeys (Chlorocebus aethiops). J. Am. Assoc. Lab. Anim. Sci. 46:58-60.
21. Gleiser, C. A., C. C. Berdjis, H. A. Hartman, and W. S. Gochenour. 1963. Pathology of experimental respiratory anthrax in Macaca mulatta. Br. J. Exp. Pathol. 44:416-426.
22. Green, B. D., L. Battisti, T. M. Koehler, C. B. Thorne, and B. E. Ivins. 1985. Demonstration of a capsule plasmid in Bacillus anthracis. Infect. Immun. 49:291-297.
23. Hail, A. S., C. A. Rossi, G. V. Ludwig, B. E. Ivins, R. F. Tammariello, and E. A. Henchal. 1999. Comparison of noninvasive sampling sites for early detection of Bacillus anthracis spores from rhesus monkeys after aerosol exposure. Mil. Med. 164:833-837.
24. Hartings, J. M., and C. J. Roy. 2004. The automated bioaerosol exposure system: preclinical platform development and a respiratory dosimetry application with nonhuman primates. J. Pharmacol. Toxicol. Methods 49:39-55.
25. Hartman, L. J., S. R. Coyne, and D. A. Norwood. 2005. Development of a novel internal positive control for Taqman based assays. Mol. Cell. Probes 19:51-59.
26. Hoffmaster, A. R., R. F. Meyer, M. P. Bowen, C. K. Marston, R. S. Weyant, G. A. Barnet, J. J. Sejvar, J. A. Jernigan, B. A. Perkins, and T. Popovic. 2002. Evaluation and validation of a real-time polymerase chain reaction assay for rapid identification of Bacillus anthracis. Emerg. Infect. Dis. 8:1178-1181.
27. Holty, J. E., D. M. Bravata, H. Liu, R. A. Olshen, K. M. McDonald, and D. K. Owens. 2006. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann. Intern. Med. 144:270-280.
28. Hurwitz, J. L., K. F. Soike, M. Y. Sangster, A. Portner, R. E. Sealy, D. H. Dawson, and C. Coleclough. 1997. Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one. Vaccine 15:533-540.
29. Ivins, B. E., P. F. Fellows, and G. O. Nelson. 1994. Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guineapigs. Vaccine 12:872-874.
30. Ivins, B. E., M. L. Pitt, P. F. Fellows, J. W. Farchaus, G. E. Benner, D. M. Waag, S. F. Little, G. W. Anderson, Jr., P. H. Gibbs, and A. M. Friedlander. 1998. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16:1141-1148.
31. Jernigan, D. B., P. L. Raghunathan, B. P. Bell, R. Brechner, E. A. Bresnitz, J. C. Butler, M. Cetron, M. Cohen, T. Doyle, M. Fischer, C. Greene, K. S. Griffith, J. Guarner, J. L. Hadler, J. A. Hayslett, R. Meyer, L. R. Petersen, M. Phillips, R. Pinner, T. Popovic, C. P. Quinn, J. Reefhius, D. Reissman, N. Rosenstein, A. Schuchat, W. J. Shieh, L. Siegal, D. L. Swerdlow, F. C. Tenover, M. Traeger, J. W. Ward, I. Weisfuse, S. Wiersma, K. Yeskey, S. Zaki, D. A. Ashford, B. A. Perkins, S. Ostroff, J. Hughes, D. Fleming, J. P. Koplan, and J. L. Gerberding for the National Anthrax Epidemiologic Investigation Team. 2002. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg. Infect. Dis. 8:1019-1028.
32. Kijek, T. M., C. A. Rossi, D. Moss, R. W. Parker, and E. A. Henchal. 2000. Rapid and sensitive immunomagnetic-electrochemiluminescent detection of staphylococcal enterotoxin B. J. Immunol. Methods 236:9-17.
33. Kobiler, D., S. Weiss, H. Levy, M. Fisher, A. Mechaly, A. Pass, and Z. Altboum. 2006. Protective antigen as a correlative marker for anthrax in animal models. Infect. Immun. 74:5871-5876.
34. Koech, D. K., J. O. Olobo, A. Wamachi, J. I. Githure, and G. D. Reid. 1992. Cellular responses of vervet monkeys (Cercopithecus aethiops) experimentally infected with Leishmania major. J. Med. Primatol. 21:375-376.
35. Leppla, S. H. 1982. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cAMP concentrations in eukaryotic cells. Proc. Natl. Acad. Sci. USA 79:3162-6133.
36. Leppla, S. H., B. E. Ivins, and J. W. Ezzell. 1985. Anthrax toxin, p 63-66. In D. Schlessinger (ed.), Microbiology - 1985. American Society for Microbiology, Washington, DC.
37. Lever, M. S., A. J. Stagg, M. Nelson, P. Pearce, D. J. Stevens, E. A. Scott, A. J. Simpson, and M. J. Fulop. 2008. Experimental respiratory anthrax infection in the common marmoset (Callithrix jacchus). Int. J. Exp. Pathol. 89:171-179.
38. Little, S. F., S. H. Leppla, and E. Cora. 1988. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect. Immun. 56:1807-1813.
39. Mikesell, P., B. E. Ivins, J. D. Ristroph, and T. M. Drier. 1983. Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect. Immun. 39:371-376.
40. Moayeri, M., and S. H. Leppla. 2004. Anthrax toxins in pathogenesis. Curr. Opin. Microbiol. 7:19-24.
41. Mock, M., and A. Fouet. 2001. Anthrax. Annu. Rev. Microbiol. 55:647-671.
42. Mourez, M. 2004. Anthrax toxins. Rev. Physiol. Biochem. Pharmacol. 152:135-164.
43. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
44. Olobo, J. O., M. M. Gicheru, and C. O. Anjili. 2001. The African green monkey model for cutaneous and visceral leishmaniasis. Trends Parasitol. 17:588-592.
45. Pandrea, I., C. Apetrei, J. Dufour, N. Dillon, J. Barbercheck, M. Metzger, B. Jacquelin, R. Bohm, P. A. Marx, F. Barre-Sinoussi, V. M. Hirsch, M. C. Müller-Trutwin, A. A. Lackner, and R. S. Veazey. 2006. Simian immunodeficiency virus SIVagm.sab infection of Caribbean African green monkeys: a new model for the study of SIV pathogenesis in natural hosts. J. Virol. 80:4858-4867.
46. Pitt, L. 2004. Nonhuman primates as a model for pneumonic plague. In Public Workshop on Animal Models and Correlates of Protection for Plague Vaccines. http://www.fda.gov/cber/minutes/plague101304t.htm.
47. Reed, D. S., C. M. Lind, L. J. Sullivan, W. D. Pratt, and M. D. Parker. 2004. Aerosol infection of cynomolgus macaques with enzootic strains of Venezuelan equine encephalitis viruses. J. Infect. Dis. 189:1013- 1017.
48. Reed, D. S., C. M. Lind, M. Lackemeyer, L. J. Sullivan, W. Pratt, and M. D. Parker. 2005. Genetically engineered, live attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus. Vaccine. 23:3139-3147.
49. Reed, D. S., T. Larsen, L. J. Sullivan, C. M. Lind, M. G. Lackemeyer, W. D. Pratt, and M. D. Parker. 2005. Aerosol exposure to western equine encephalitis virus causes fever and encephalitis in cynomolgus macaques. J. Infect. Dis. 192:1173-1182.
50. Reed, D. S., M. G. Lackemeyer, N. L. Garza, S. Norris, S. Gamble, L. J. Sullivan, C. M. Lind, and J. L. Raymond. 2007. Severe encephalitis in cynomolgus macaques exposed to aerosolized eastern equine encephalitis virus. J. Infect. Dis. 196:441-450.
51. Sirard, J. C., M. Mock, and A. Fouet. 1994. The three Bacillus anthracis toxin genes are coordinately regulated by bicarbonate and temperature. J. Bacteriol. 176:5188-5192.
52. Smith, D. R., C. A. Rossi, T. M. Kijek, E. A. Henchal, and G. V. Ludwig. 2001. Comparison of dissociation-enhanced lanthanide fluorescent immunoassays to enzyme-linked immunosorbent assays for detection of staphylococcal enterotoxin B, Yersinia pestis-specific F1 antigen, and Venezuelan equine encephalitis virus. Clin. Diagn. Lab. Immunol. 8:1070-1075.
53. Twenhafel, N. A., E. Leffel, and M. L. Pitt. 2007. Pathology of inhalational anthrax infection in the African green monkey. Vet. Pathol. 44:716-721.
54. Uchida, I., T. Sekizaki, K. Hashimoto, and N. Terakado. 1985. Association of the encapsulation of Bacillus anthracis with a 60 megadalton plasmid. J. Gen. Microbiol. 131:363-367.
55. Vasconcelos, D., R. Barnewall, M. Babin, R. Hunt, J. Estep, C. Nielsen, R. Carnes, and J. Carney. 2003. Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis). Lab. Investig. 83:1201-1209.